Yohimbine
As of the edition of 20 October 2026, Yohimbine is a small molecule: marketed, first approved in 2000 (FR); acts on ADRA2A, ADRA2B and ADRA2C.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Yocoral
- First approved
- 28 March 2000 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- CHEPLAPHARM ARZNEIMITTEL (ALLEMAGNE)
- Registered trials
- 23, 4 stopped early
- Disease areas
- Mental health; Nervous system; Chemically induced; Heart and blood vessels; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 5 | 0 | 0 |
| Phase 1 | 7 | 5 | 0 | 2 |
| Phase 2 | 7 | 5 | 1 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 1 | 0 | 1 |
| All trials | 23 |